中文简体
中文繁体
English
ABOUT IASO
Company Overview
Management Team
Scientific Advisory Board
Partnership
SCIENCE & PRODUCTS
Pipeline
Technology Platforms
Manufacturing
Publictaions
Expanded Access
NEWS
Press Release
Media Report
CAREERS
Working at IASO
Opportunities
CONTACT
NEWS
Press Release
Media Report
Search
01
2021-06
Application for clinical trial of the 2nd indication of IASO Biotherapeutics’ fully human CD19/CD22 dual-targeted CAR-T drug accepted by NMPA
23
2021-05
IASO Announced Acceptance of IND Application by NMPA for CT120, a Fully Human CD19/CD22 Dual-Targeting CAR-T Therapy
23
2021-02
The BCMA CAR-T Co-developed by IASO Biotherapeutics and Innovent was Granted Breakthrough Therapy Designation by the NMPA for the Treatment of Relapsed/Refractory Multiple Myeloma
21
2020-12
IASO BIO’s Cell Therapy Summit Forum Successfully Held in Nanjing
14
2020-10
IASO Bio Appoints Dr. Biao Zheng as Chief Scientific Officer and Dr. Wen Wang as Chief Medical Officer
23
2020-03
IASO Biotherapeutics Raises $60 Million in Series B Financing led by GL Ventures to Advance Cell Therapies for Cancer Care
11
2019-09
NMPA Approves IND Application for CT103A, A Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma codeveloped by IASO BIO and Innovent Bio
18
2019-06
Clinical Results of Fully-human BCMA CAR-T for the Treatment of Relapsed/Refractory Multiple Myeloma Co-developed by IASO BIO and Innovent Presented at the 2019 ASCO and EHA Annual Meetings
<
4
5
6
7
8
>
